PE20231031A1 - Regimen de dosis baja y formulacion de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo - Google Patents
Regimen de dosis baja y formulacion de un compuesto 5-metil-1,2,4-oxadiazol-3-iloInfo
- Publication number
- PE20231031A1 PE20231031A1 PE2023000107A PE2023000107A PE20231031A1 PE 20231031 A1 PE20231031 A1 PE 20231031A1 PE 2023000107 A PE2023000107 A PE 2023000107A PE 2023000107 A PE2023000107 A PE 2023000107A PE 20231031 A1 PE20231031 A1 PE 20231031A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- compound
- formulation
- dose regimen
- ylo
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 2
- 102100030122 Protein O-GlcNAcase Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108010045982 hexosaminidase C Proteins 0.000 abstract 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 abstract 2
- FRVXHWNHGWUTQO-CABZTGNLSA-N N-[4-fluoro-5-[[(2S,4S)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1N=C(SC=1CN1[C@H](C[C@H](CC1)OCC1=NOC(=N1)C)C)NC(C)=O FRVXHWNHGWUTQO-CABZTGNLSA-N 0.000 abstract 1
- 208000034799 Tauopathies Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055362P | 2020-07-23 | 2020-07-23 | |
| PCT/US2021/042877 WO2022020663A1 (en) | 2020-07-23 | 2021-07-23 | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231031A1 true PE20231031A1 (es) | 2023-07-10 |
Family
ID=77338898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023000107A PE20231031A1 (es) | 2020-07-23 | 2021-07-23 | Regimen de dosis baja y formulacion de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo |
Country Status (21)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3243602A1 (en) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107735190B (zh) * | 2016-07-22 | 2019-11-26 | 深圳市大富科技股份有限公司 | Usb金属管件加工设备及其上模板 |
| TWI654978B (zh) * | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5-甲基-1,2,4-二唑-3-基化合物 |
| EP3829634A1 (en) * | 2018-07-31 | 2021-06-09 | Eli Lilly and Company | Combination therapy |
-
2021
- 2021-07-21 TW TW110126729A patent/TW202220650A/zh unknown
- 2021-07-21 AR ARP210102050A patent/AR123031A1/es unknown
- 2021-07-23 EP EP21755253.8A patent/EP4185291B1/en active Active
- 2021-07-23 CA CA3186808A patent/CA3186808A1/en active Pending
- 2021-07-23 IL IL300023A patent/IL300023A/en unknown
- 2021-07-23 JP JP2023504346A patent/JP2023535034A/ja active Pending
- 2021-07-23 CN CN202180063288.5A patent/CN116323604A/zh active Pending
- 2021-07-23 KR KR1020237005839A patent/KR20230043905A/ko not_active Withdrawn
- 2021-07-23 US US18/005,245 patent/US20230338349A1/en active Pending
- 2021-07-23 ES ES21755253T patent/ES3039536T3/es active Active
- 2021-07-23 WO PCT/US2021/042877 patent/WO2022020663A1/en not_active Ceased
- 2021-07-23 BR BR112023000975A patent/BR112023000975A2/pt unknown
- 2021-07-23 MX MX2023000993A patent/MX2023000993A/es unknown
- 2021-07-23 PH PH1/2023/550177A patent/PH12023550177A1/en unknown
- 2021-07-23 AU AU2021312894A patent/AU2021312894B2/en active Active
- 2021-07-23 PE PE2023000107A patent/PE20231031A1/es unknown
-
2023
- 2023-01-19 CL CL2023000194A patent/CL2023000194A1/es unknown
- 2023-01-19 CO CONC2023/0000594A patent/CO2023000594A2/es unknown
- 2023-01-20 DO DO2023000009A patent/DOP2023000009A/es unknown
- 2023-01-23 EC ECSENADI20235057A patent/ECSP23005057A/es unknown
- 2023-01-23 JO JOJO/P/2023/0018A patent/JOP20230018A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023000194A1 (es) | 2023-07-21 |
| EP4185291C0 (en) | 2025-07-09 |
| CA3186808A1 (en) | 2022-01-27 |
| AU2021312894B2 (en) | 2025-09-11 |
| IL300023A (en) | 2023-03-01 |
| BR112023000975A2 (pt) | 2023-02-07 |
| KR20230043905A (ko) | 2023-03-31 |
| CN116323604A (zh) | 2023-06-23 |
| ES3039536T3 (en) | 2025-10-22 |
| ECSP23005057A (es) | 2023-02-28 |
| AR123031A1 (es) | 2022-10-26 |
| MX2023000993A (es) | 2023-03-01 |
| PH12023550177A1 (en) | 2024-03-18 |
| AU2021312894A1 (en) | 2023-02-23 |
| EP4185291A1 (en) | 2023-05-31 |
| US20230338349A1 (en) | 2023-10-26 |
| JOP20230018A1 (ar) | 2023-01-23 |
| DOP2023000009A (es) | 2023-02-15 |
| CO2023000594A2 (es) | 2023-01-26 |
| WO2022020663A1 (en) | 2022-01-27 |
| EP4185291B1 (en) | 2025-07-09 |
| JP2023535034A (ja) | 2023-08-15 |
| TW202220650A (zh) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240881A1 (es) | Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t | |
| CO2019007711A2 (es) | N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga | |
| JOP20230304A1 (ar) | نظائر تريازولو-بيريميدين لعلاج الأمراض المرتبطة بتثبيط متلازمة Werner RecQ هيليكاز (WRN) | |
| PE20210401A1 (es) | Composiciones farmaceuticas que comprenden meloxicam | |
| PE20160195A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
| TW200637558A (en) | Solid, modified-release pharmaceutical dosage forms which can be administered orally | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| AR020727A1 (es) | Uso de compuestos derivados 3-amino-4-aril-maleimidas para la preparacion de medicamentos para condiciones asociadas a una necesidad de inhibicion de lagsk-3, dichos compuestos, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| PE20212245A1 (es) | Composicion farmaceutica oral que comprende acido 3-[5-(2-fluorofenil)- [1,2,4]oxadiazol-3-il]-benzoico | |
| AR048431A1 (es) | Formulaciones galenicas de compuestos organicos | |
| HRP20140783T1 (hr) | Uporaba epotilona d u lijeäśenju tau-povezanih bolesti ukljuäśujuä†i alzheimerovu bolest | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| MA46268A (fr) | Dérivés de 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma | |
| EA202190586A1 (ru) | N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6 | |
| PE20241327A1 (es) | Tratamiento de trastornos hepaticos con un agonista del thr-beta | |
| CL2024003616A1 (es) | Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| EA202190544A1 (ru) | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний | |
| US12414935B2 (en) | Compounds and methods for the treatment of parasitic diseases | |
| CO2023000594A2 (es) | Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4- oxadiazol-3-ilo | |
| AR114930A1 (es) | Composición farmacéutica | |
| CO2026000726A2 (es) | Una forma farmacéutica sólida de dosificación bucodispersable de safinamida | |
| AR029666A1 (es) | Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina | |
| RU2007104774A (ru) | Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы | |
| PE20040706A1 (es) | Derivado especifico de amina ciclica y sus sales farmaceuticamente aceptables involucrados en la prevencion de la insuficiencia cardiaca | |
| HRP20251471T1 (hr) | Postupci liječenja poremećaja hiperaktivnosti s deficitom pažnje korištenjem inhibitora kdm1a kao što je spoj vafidemstat |